Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 11 | 2024 | 3049 | 1.640 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 255 | 0.980 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 400 | 0.900 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 96 | 0.670 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 60 | 0.650 |
Why?
|
| Neuropeptide Y | 1 | 2018 | 5 | 0.620 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2018 | 14 | 0.580 |
Why?
|
| Cyclic AMP | 1 | 2018 | 91 | 0.570 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 1436 | 0.520 |
Why?
|
| Up-Regulation | 1 | 2018 | 462 | 0.510 |
Why?
|
| Depression | 2 | 2018 | 600 | 0.500 |
Why?
|
| Mice | 8 | 2024 | 5965 | 0.420 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2024 | 125 | 0.400 |
Why?
|
| Animals | 9 | 2024 | 13523 | 0.360 |
Why?
|
| Osteolysis | 2 | 2022 | 75 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 858 | 0.290 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 340 | 0.270 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 116 | 0.220 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 132 | 0.210 |
Why?
|
| Humans | 12 | 2024 | 52336 | 0.210 |
Why?
|
| Signal Transduction | 2 | 2020 | 1716 | 0.190 |
Why?
|
| Glycolysis | 1 | 2022 | 73 | 0.190 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 121 | 0.180 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2021 | 48 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 205 | 0.170 |
Why?
|
| Stem Cell Niche | 1 | 2020 | 12 | 0.170 |
Why?
|
| Drug Synergism | 1 | 2020 | 148 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2019 | 278 | 0.170 |
Why?
|
| Bone Resorption | 1 | 2022 | 302 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 110 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2020 | 190 | 0.160 |
Why?
|
| Prognosis | 2 | 2024 | 2094 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 188 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2018 | 39 | 0.150 |
Why?
|
| Transcription Factors | 1 | 2022 | 574 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 606 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 364 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2022 | 1029 | 0.150 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 87 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 110 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 126 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 1006 | 0.140 |
Why?
|
| Colitis | 1 | 2018 | 51 | 0.140 |
Why?
|
| Disease Progression | 1 | 2020 | 870 | 0.140 |
Why?
|
| Male | 4 | 2024 | 26696 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 240 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 278 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2018 | 117 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2018 | 186 | 0.130 |
Why?
|
| Phosphorylation | 1 | 2018 | 531 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2020 | 494 | 0.130 |
Why?
|
| Inflammation | 1 | 2018 | 642 | 0.110 |
Why?
|
| Cystatin M | 2 | 2024 | 19 | 0.100 |
Why?
|
| B-Cell Maturation Antigen | 2 | 2024 | 98 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5407 | 0.080 |
Why?
|
| Ferritins | 1 | 2024 | 36 | 0.050 |
Why?
|
| Female | 1 | 2024 | 28105 | 0.050 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 79 | 0.050 |
Why?
|
| Antibodies | 1 | 2024 | 152 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1484 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2024 | 488 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 167 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2023 | 239 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 270 | 0.050 |
Why?
|
| RANK Ligand | 1 | 2022 | 187 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 563 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 643 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2022 | 674 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2022 | 428 | 0.040 |
Why?
|
| Genes, myc | 1 | 2019 | 39 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 8 | 0.040 |
Why?
|
| Mucin-2 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Muramidase | 1 | 2018 | 15 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 1110 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 88 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2018 | 909 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1903 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 6578 | 0.020 |
Why?
|